Metabolic Side-effects for Second-generation Antipsychotics
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01280396|
Recruitment Status : Completed
First Posted : January 20, 2011
Last Update Posted : May 3, 2018
Second-generation antipsychotics (SGAs), including clozapine, are commonly used nowadays as treatment for psychosis. There are increasing concerns about their related metabolic side-effects over weight gain, risks to cause glucose intolerance and hyperlipidemia, and a specific condition known as metabolic syndrome. All these side-effects might be associated with the increased risk of cardiovascular diseases and diabetes mellitus.
This study is to analyze the simple physical measurements (weight and height) and venous blood tests (for fasting blood glucose and lipid) results collected routinely since 2008 (recommended by the local hospital authority as a territory-wide "SGAs Monitoring Program") from those outpatients receiving SGAs (amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) and/or clozapine, at a local psychiatric outpatient clinic in Hong Kong. The investigators hypothesized that there should be differential risks on metabolic side-effects amongst these SGAs.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||241 participants|
|Official Title:||Metabolic Side-effects in Patients Receiving Clozapine and Second-generation Antipsychotics in an Outpatient Clinic|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2014|
patients receiving SGAs
- development of metabolic syndrome according to IDF criteria [ Time Frame: 1 year ]post treatment with second generation antipsychotics
- change in BMI [ Time Frame: 1 year ]post treatment with second generation antipsychotics
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01280396
|Western Psychiatric Centre|
|Hong Kong, Hong Kong, 00000|
|Principal Investigator:||Albert Kar Kin Chung, MBBS||Department of Psychiatry, Queen Mary Hospital|